Briefs

(26 March 2009, Cambridge, UK) Linguamatics Ltd, a leader in enterprise text mining for the life science and other markets, today announced that Novo Nordisk, a world-leader in diabetes care, has entered into a multi-year agreement to use the I2E semantic knowledge discovery platform for text mining. At Novo Nordisk I2E will be used to mine published literature and internal information sources to provide business critical intelligence for R&D decision makers. Financial details of the agreement were not disclosed.

I2E's natural language processing (NLP) based text mining delivers relevant, high quality and current insights from content such as biomedical literature, internal reports, patents and news sources to inform business decisions. It is used for a wide variety of life science applications including biomarker discovery, target selection, safety/tox, pharmacogenomics, systems biology, competitor intelligence and sentiment analysis.

For further information on Linguamatics products and solutions, visit www.linguamatics.com.